Udenyca

See full labeling. For autoinjector: not suitable for pediatrics weighing <45kg. For autoinjector, syringe: administer into abdomen, thighs, back of upper arm, or upper outer area of buttocks; rotate inj sites. For on-body injector (OBI): not recommended for hematopoietic subsyndrome of acute radiation syndrome and not studied in pediatric patients; health care provider must use only the co-packaged prefilled syringe and apply OBI to abdomen or back of upper arm. ≥45kg: On myelosuppressive chemotherapy: 6mg SC once per chemotherapy cycle. Do not give between 14 days before and 24 hours after chemotherapy. Hematopoietic subsyndrome of acute radiation syndrome:  6mg SC each for 2 doses, given 1 week apart. Administer the 1^st dose as soon as possible after suspected or confirmed exposure to radiation levels >2 gray (Gy). Both: Pediatrics (31–44kg): 4mg; (21–30kg): 2.5mg; (10–20kg): 1.5mg; (<10kg): 0.1mg/kg. Direct administration of prefilled syringe with doses <6mg is not recommended.